Update on treatment recommendations from the fourth international workshop on Waldenström's macroglobulinemia

Meletios Athanasios Dimopoulos, Morie A. Gertz, Efstathios Kastritis, Ramon Garcia-Sanz, Eva K. Kimby, Veronique LeBlond, Jean Paul Fermand, Giampaolo Merlini, Pierre Morel, Enrica Morra, Enrique M. Ocio, Roger Owen, Irene M. Ghobrial, John Seymour, Robert A. Kyle, Steven P. Treon

Research output: Contribution to journalArticle

156 Citations (Scopus)

Abstract

Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder characterized by lymphoplasmacytic bone marrow infiltration along with an immunoglobulin M (lgM) monoclonal gammopathy. Patients with disease-related cytopenias, bulky adenopathy or organomegaly, symptomatic hyperviscosity, severe neuropathy, amyloidosis, cryoglobulinemia, cold agglutinin disease, or evidence of disease transformation should be considered for immediate therapy. Initiation of therapy should not be based on serum lgM levels alone, and asymptomatic patients should be observed. Individual patient considerations should be considered when deciding on a first-line agent including the presence of cytopenias, need for rapid disease control, age, and candidacy for autologous transplantation. Therapeutic outcomes should be evaluated using updated criteria. As part of the Fourth International Workshop on Waldenström's Macroglobulinemia, a consensus panel updated its recommendations on both first-line and salvage therapy in view of recently published and ongoing clinical trials. The panel considered encouraging results from recent studies of first-line combinations such as rituximab with nucleoside analogs with or without alkylating agents or with cyclophosphamide-based therapies (eg, cyclophosphamide, doxorubicin, vincristine, and prednisone or cyclophosphamide and dexamethasone) or the combination of rituximab with thalidomide. Such therapeutic approaches are likely to yield responses at least as good as, if not better than, monotherapy with any of the alkylating agents, nucleoside analogs, or rituximab. In the salvage setting, reuse of a first-line regimen or use of a different regimen should be considered along with bortezomib, alemtuzumab, autologous transplantation, and, in selected circumstances, allogeneic transplantation. Finally, the panel reaffirmed its encouragement of the active enrollment of patients with WM onto innovative clinical trials whenever possible.

Original languageEnglish
Pages (from-to)120-126
Number of pages7
JournalJournal of Clinical Oncology
Volume27
Issue number1
DOIs
Publication statusPublished - Jan 1 2009

Fingerprint

Waldenstrom Macroglobulinemia
Education
Cyclophosphamide
Autologous Transplantation
Alkylating Agents
Nucleosides
Clinical Trials
Therapeutics
Cryoglobulinemia
Autoimmune Hemolytic Anemia
Salvage Therapy
Paraproteinemias
Thalidomide
Lymphoproliferative Disorders
Homologous Transplantation
Vincristine
Amyloidosis
Prednisone
Doxorubicin
Dexamethasone

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dimopoulos, M. A., Gertz, M. A., Kastritis, E., Garcia-Sanz, R., Kimby, E. K., LeBlond, V., ... Treon, S. P. (2009). Update on treatment recommendations from the fourth international workshop on Waldenström's macroglobulinemia. Journal of Clinical Oncology, 27(1), 120-126. https://doi.org/10.1200/JCO.2008.17.7865

Update on treatment recommendations from the fourth international workshop on Waldenström's macroglobulinemia. / Dimopoulos, Meletios Athanasios; Gertz, Morie A.; Kastritis, Efstathios; Garcia-Sanz, Ramon; Kimby, Eva K.; LeBlond, Veronique; Fermand, Jean Paul; Merlini, Giampaolo; Morel, Pierre; Morra, Enrica; Ocio, Enrique M.; Owen, Roger; Ghobrial, Irene M.; Seymour, John; Kyle, Robert A.; Treon, Steven P.

In: Journal of Clinical Oncology, Vol. 27, No. 1, 01.01.2009, p. 120-126.

Research output: Contribution to journalArticle

Dimopoulos, MA, Gertz, MA, Kastritis, E, Garcia-Sanz, R, Kimby, EK, LeBlond, V, Fermand, JP, Merlini, G, Morel, P, Morra, E, Ocio, EM, Owen, R, Ghobrial, IM, Seymour, J, Kyle, RA & Treon, SP 2009, 'Update on treatment recommendations from the fourth international workshop on Waldenström's macroglobulinemia', Journal of Clinical Oncology, vol. 27, no. 1, pp. 120-126. https://doi.org/10.1200/JCO.2008.17.7865
Dimopoulos, Meletios Athanasios ; Gertz, Morie A. ; Kastritis, Efstathios ; Garcia-Sanz, Ramon ; Kimby, Eva K. ; LeBlond, Veronique ; Fermand, Jean Paul ; Merlini, Giampaolo ; Morel, Pierre ; Morra, Enrica ; Ocio, Enrique M. ; Owen, Roger ; Ghobrial, Irene M. ; Seymour, John ; Kyle, Robert A. ; Treon, Steven P. / Update on treatment recommendations from the fourth international workshop on Waldenström's macroglobulinemia. In: Journal of Clinical Oncology. 2009 ; Vol. 27, No. 1. pp. 120-126.
@article{6e285e8f39fb48be992a3277ec279204,
title = "Update on treatment recommendations from the fourth international workshop on Waldenstr{\"o}m's macroglobulinemia",
abstract = "Waldenstr{\"o}m macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder characterized by lymphoplasmacytic bone marrow infiltration along with an immunoglobulin M (lgM) monoclonal gammopathy. Patients with disease-related cytopenias, bulky adenopathy or organomegaly, symptomatic hyperviscosity, severe neuropathy, amyloidosis, cryoglobulinemia, cold agglutinin disease, or evidence of disease transformation should be considered for immediate therapy. Initiation of therapy should not be based on serum lgM levels alone, and asymptomatic patients should be observed. Individual patient considerations should be considered when deciding on a first-line agent including the presence of cytopenias, need for rapid disease control, age, and candidacy for autologous transplantation. Therapeutic outcomes should be evaluated using updated criteria. As part of the Fourth International Workshop on Waldenstr{\"o}m's Macroglobulinemia, a consensus panel updated its recommendations on both first-line and salvage therapy in view of recently published and ongoing clinical trials. The panel considered encouraging results from recent studies of first-line combinations such as rituximab with nucleoside analogs with or without alkylating agents or with cyclophosphamide-based therapies (eg, cyclophosphamide, doxorubicin, vincristine, and prednisone or cyclophosphamide and dexamethasone) or the combination of rituximab with thalidomide. Such therapeutic approaches are likely to yield responses at least as good as, if not better than, monotherapy with any of the alkylating agents, nucleoside analogs, or rituximab. In the salvage setting, reuse of a first-line regimen or use of a different regimen should be considered along with bortezomib, alemtuzumab, autologous transplantation, and, in selected circumstances, allogeneic transplantation. Finally, the panel reaffirmed its encouragement of the active enrollment of patients with WM onto innovative clinical trials whenever possible.",
author = "Dimopoulos, {Meletios Athanasios} and Gertz, {Morie A.} and Efstathios Kastritis and Ramon Garcia-Sanz and Kimby, {Eva K.} and Veronique LeBlond and Fermand, {Jean Paul} and Giampaolo Merlini and Pierre Morel and Enrica Morra and Ocio, {Enrique M.} and Roger Owen and Ghobrial, {Irene M.} and John Seymour and Kyle, {Robert A.} and Treon, {Steven P.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1200/JCO.2008.17.7865",
language = "English",
volume = "27",
pages = "120--126",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Update on treatment recommendations from the fourth international workshop on Waldenström's macroglobulinemia

AU - Dimopoulos, Meletios Athanasios

AU - Gertz, Morie A.

AU - Kastritis, Efstathios

AU - Garcia-Sanz, Ramon

AU - Kimby, Eva K.

AU - LeBlond, Veronique

AU - Fermand, Jean Paul

AU - Merlini, Giampaolo

AU - Morel, Pierre

AU - Morra, Enrica

AU - Ocio, Enrique M.

AU - Owen, Roger

AU - Ghobrial, Irene M.

AU - Seymour, John

AU - Kyle, Robert A.

AU - Treon, Steven P.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder characterized by lymphoplasmacytic bone marrow infiltration along with an immunoglobulin M (lgM) monoclonal gammopathy. Patients with disease-related cytopenias, bulky adenopathy or organomegaly, symptomatic hyperviscosity, severe neuropathy, amyloidosis, cryoglobulinemia, cold agglutinin disease, or evidence of disease transformation should be considered for immediate therapy. Initiation of therapy should not be based on serum lgM levels alone, and asymptomatic patients should be observed. Individual patient considerations should be considered when deciding on a first-line agent including the presence of cytopenias, need for rapid disease control, age, and candidacy for autologous transplantation. Therapeutic outcomes should be evaluated using updated criteria. As part of the Fourth International Workshop on Waldenström's Macroglobulinemia, a consensus panel updated its recommendations on both first-line and salvage therapy in view of recently published and ongoing clinical trials. The panel considered encouraging results from recent studies of first-line combinations such as rituximab with nucleoside analogs with or without alkylating agents or with cyclophosphamide-based therapies (eg, cyclophosphamide, doxorubicin, vincristine, and prednisone or cyclophosphamide and dexamethasone) or the combination of rituximab with thalidomide. Such therapeutic approaches are likely to yield responses at least as good as, if not better than, monotherapy with any of the alkylating agents, nucleoside analogs, or rituximab. In the salvage setting, reuse of a first-line regimen or use of a different regimen should be considered along with bortezomib, alemtuzumab, autologous transplantation, and, in selected circumstances, allogeneic transplantation. Finally, the panel reaffirmed its encouragement of the active enrollment of patients with WM onto innovative clinical trials whenever possible.

AB - Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder characterized by lymphoplasmacytic bone marrow infiltration along with an immunoglobulin M (lgM) monoclonal gammopathy. Patients with disease-related cytopenias, bulky adenopathy or organomegaly, symptomatic hyperviscosity, severe neuropathy, amyloidosis, cryoglobulinemia, cold agglutinin disease, or evidence of disease transformation should be considered for immediate therapy. Initiation of therapy should not be based on serum lgM levels alone, and asymptomatic patients should be observed. Individual patient considerations should be considered when deciding on a first-line agent including the presence of cytopenias, need for rapid disease control, age, and candidacy for autologous transplantation. Therapeutic outcomes should be evaluated using updated criteria. As part of the Fourth International Workshop on Waldenström's Macroglobulinemia, a consensus panel updated its recommendations on both first-line and salvage therapy in view of recently published and ongoing clinical trials. The panel considered encouraging results from recent studies of first-line combinations such as rituximab with nucleoside analogs with or without alkylating agents or with cyclophosphamide-based therapies (eg, cyclophosphamide, doxorubicin, vincristine, and prednisone or cyclophosphamide and dexamethasone) or the combination of rituximab with thalidomide. Such therapeutic approaches are likely to yield responses at least as good as, if not better than, monotherapy with any of the alkylating agents, nucleoside analogs, or rituximab. In the salvage setting, reuse of a first-line regimen or use of a different regimen should be considered along with bortezomib, alemtuzumab, autologous transplantation, and, in selected circumstances, allogeneic transplantation. Finally, the panel reaffirmed its encouragement of the active enrollment of patients with WM onto innovative clinical trials whenever possible.

UR - http://www.scopus.com/inward/record.url?scp=58149350437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149350437&partnerID=8YFLogxK

U2 - 10.1200/JCO.2008.17.7865

DO - 10.1200/JCO.2008.17.7865

M3 - Article

VL - 27

SP - 120

EP - 126

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -